Bovine VEGF-A ELISA Kit

Vascular endothelial growth factor A (VEGF-A) is a glycosylated mitogen that specifically acts on endothelial cells and has various other effects including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Alternatively spliced transcript variants of VEGF-A, encoding either freely secreted or cell-associated isoforms, have been characterized.[1]
As its name implies, VEGF-A activity has been studied mostly on cells of the vascular endothelium, although it does have effects on a number of other cell types (e.g., monocytes/macrophages, neurons, cancer cells, kidney epithelial cells). In vitro, VEGF-A has been shown to stimulate endothelial cell mitogenesis and cell migration. VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor.

In humans, elevated levels of this protein are linked to POEMS syndrome, also known as Crow-Fukase syndrome.[2] Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy.[3]

Bovine VEGF-A ELISA Kit Catalog No. E11-808

References

1. Mattei MG, Borg JP, Rosnet O, Marmé D, Birnbaum D (February 1996). "Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12-p21 and 14q24-q31 regions, respectively". Genomics 32 (1): 168–9.

2. Dispenzieri A (November 2007). "POEMS syndrome". Blood Rev. 21 (6): 285–99.

3. Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima T, Kurimoto M, Murakami T, Kimura T, Takagi H (March 2005). "Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy". Am. J. Ophthalmol. 139 (3): 476–81.